Your browser doesn't support javascript.
loading
Semaglutide, a newly available glucagon-like peptide receptor agonist, shows remarkable favorable effects in hemodialysis patients with obesity and Type 2 diabetes.
Saito, Suguru; Nakao, Toshiyuki.
Affiliation
  • Saito S; Department of Nephrology, Tokyo Medical University, Tokyo, Japan.
  • Nakao T; Organization for Kidney Metabolic Disease Treatment, Tokyo, Japan.
Ther Apher Dial ; 26(1): 242-243, 2022 02.
Article in En | MEDLINE | ID: mdl-33830659
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Renal Dialysis / Diabetes Mellitus, Type 2 / Glucagon-Like Peptides / Glucagon-Like Peptide Receptors / Kidney Failure, Chronic / Obesity Limits: Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Ther Apher Dial Journal subject: HEMATOLOGIA Year: 2022 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Renal Dialysis / Diabetes Mellitus, Type 2 / Glucagon-Like Peptides / Glucagon-Like Peptide Receptors / Kidney Failure, Chronic / Obesity Limits: Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Ther Apher Dial Journal subject: HEMATOLOGIA Year: 2022 Document type: Article Affiliation country: